TP53 status for prediction of sensitivity to taxane versus non-taxane neoadjuvant chemotherapy in breast cancer (EORTC 10994/BIG 1-00): a randomised phase 3 trial.
about
The rebel angel: mutant p53 as the driving oncogene in breast cancer.p53-mediated senescence impairs the apoptotic response to chemotherapy and clinical outcome in breast cancer.Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013MICADo - Looking for Mutations in Targeted PacBio Cancer Data: An Alignment-Free MethodResistance to Taxanes in Triple-Negative Breast Cancer Associates with the Dynamics of a CD49f+ Tumor-Initiating Population.Pathological complete response after neoadjuvant chemotherapy is an independent predictive factor irrespective of simplified breast cancer intrinsic subtypes: a landmark and two-step approach analyses from the EORTC 10994/BIG 1-00 phase III trial.Optimal approach in early breast cancer: Adjuvant and neoadjuvant treatment.Prognostic interaction between expression of p53 and estrogen receptor in patients with node-negative breast cancer: results from IBCSG Trials VIII and IXCan biomarker assessment on circulating tumor cells help direct therapy in metastatic breast cancer?Value of TP53 status for predicting response to neoadjuvant chemotherapy in breast cancer: a meta-analysis.TP53 status predicts long-term survival in locally advanced breast cancer after primary chemotherapy.A Canadian national expert consensus on neoadjuvant therapy for breast cancer: linking practice to evidence and beyondHumanization of the mouse mammary gland by replacement of the luminal layer with genetically engineered preneoplastic human cellsTreatment-induced cell cycle kinetics dictate tumor response to chemotherapyMeta-analysis of organ-specific differences in the structure of the immune infiltrate in major malignancies.Efficacy and safety analysis of trastuzumab and paclitaxel based regimen plus carboplatin or epirubicin as neoadjuvant therapy for clinical stage II-III, HER2-positive breast cancer patients: a phase 2, open-label, multicenter, randomized trial.Prognostic and predictive value of TP53 mutations in node-positive breast cancer patients treated with anthracycline- or anthracycline/taxane-based adjuvant therapy: results from the BIG 02-98 phase III trial.Immunohistochemical detection of Polo-like kinase-1 (PLK1) in primary breast cancer is associated with TP53 mutation and poor clinical outcomBreast Cancer Biomarkers: Utility in Clinical Practice.P53 and its molecular basis to chemoresistance in breast cancer.Mapping genetic alterations causing chemoresistance in cancer: identifying the roads by tracking the drivers.Optimal adjuvant chemotherapy in breast cancer: selection of agents.Management of locally advanced breast cancer-perspectives and future directions.Surrogate marker analysis in cancer clinical trials through time-to-event mediation techniques.Deciphering and Targeting Oncogenic Mutations and Pathways in Breast Cancer.Somatic TP53 Mutations in the Era of Genome Sequencing.Identification of SNPs associated with response of breast cancer patients to neoadjuvant chemotherapy in the EORTC-10994 randomized phase III trial.Mutant p53 accumulation in human breast cancer is not an intrinsic property or dependent on structural or functional disruption but is regulated by exogenous stress and receptor status.TP53 mutation-correlated genes predict the risk of tumor relapse and identify MPS1 as a potential therapeutic kinase in TP53-mutated breast cancers.TP53 mutations are associated with higher rates of pathologic complete response to anthracycline/cyclophosphamide-based neoadjuvant chemotherapy in operable primary breast cancer.Role of TP53 mutations in triple negative and HER2-positive breast cancer treated with neoadjuvant anthracycline/taxane-based chemotherapy.Validation of a yeast functional assay for p53 mutations using clonal sequencing.Effect of antitumor treatments on triple-negative breast cancer patients: A PRISMA-compliant network meta-analysis of randomized controlled trials.Long-term safety and survival outcomes from the Scandinavian Breast Group 2004-1 randomized phase II trial of tailored dose-dense adjuvant chemotherapy for early breast cancer.PIK3CA mutations and their response to neoadjuvant treatment in early breast cancer: A systematic review and meta-analysis.Neoadjuvant chemotherapy regimens in treatment of breast cancer: a systematic review and network meta-analysis protocol.Impact of chemotactic factors and receptors on the cancer immune infiltrate: a bioinformatics study revealing homogeneity and heterogeneity among patient cohortsPrognostic significance of p16 & p53 immunohistochemical expression in triple negative breast cancerBRCA-1 methylation and TP53 mutation in triple-negative breast cancer patients without pathological complete response to taxane-based neoadjuvant chemotherapy
P2860
Q27686765-8BD28D11-2D1B-45A1-B961-DD91434DD29DQ27851827-152A72E4-37A0-4EA4-B7F7-DF5F9AFA09B0Q30543788-C840BA98-1FBF-41C7-9EDC-D77965D8946EQ31150879-7C40B709-ECEE-4252-833C-4952147324D3Q33659361-4F396AF8-E896-4AC4-B7C7-4E52D7661190Q33683120-DD48B5A4-4F64-425B-8389-171D8878D48AQ33698446-5FD822B0-ED97-4759-BE3D-A43BED86D960Q33739357-6371287B-8822-42B7-BBAC-B919F8A55083Q33820233-6D17F4F9-902A-4829-A83B-593D07B611ECQ34328227-C613D4A6-D1EF-4C15-8274-FA1CA85E15BFQ34576275-8720292F-C8BE-45C2-8EA7-674DBDAEF025Q35239617-1BD12E15-3DCD-4203-AC64-C776001F24A6Q35530169-2D54239D-4C9C-4AE0-AF52-DE649B3A6B58Q35740145-AE5E7F58-92AF-45BB-A813-313146496970Q35828467-17986C23-8708-4A1D-AAB4-26E55B26117AQ36210992-53C24D3B-2185-4E42-8438-E74F96EF6D11Q36245341-C7466D2A-9EC6-4EE1-AF81-E9FAFBEFCF55Q36245509-DA125243-3501-4A84-8EDB-361F6235826EQ37441159-0A018C4B-E19C-4956-B4A8-472B37C650BFQ37982133-4638FC2B-EF01-4792-8628-EC3B1E57638EQ38087850-93EB15F6-7AE3-4B06-97F4-5434771E064FQ38235713-EC17F82F-5E9F-4993-AD22-40295C6F4729Q38350939-4DCCF122-0205-41AD-A7C6-7C45B2C2714AQ38829245-5914ABB5-9759-4B40-9B3F-CFD73FD6C200Q38888022-8E3C70DF-E81E-47A4-9C4D-89E0AC52495BQ38922539-B1986C47-6126-4612-9AA6-9C1A7FF06953Q38981856-7DBD3586-9FA3-4873-8848-E940AC64173BQ39009607-01541EEB-9B66-40AF-A5CC-8CA6CB5A92F9Q39030842-6627C3B9-263B-4879-A6FC-6CD53DB34E1BQ41519051-E8562CC1-BCB2-42BC-AA6B-5CCA8D119F58Q42315543-71C8BA8E-B7EA-442D-AD7B-56C66708140DQ44145277-7220453A-E8CC-44B0-802A-09A2FA28900EQ47121796-4228ACC2-6A0C-4960-A4B7-42A1AAA82637Q47391721-B07C6A26-A791-4F7E-8A7E-708D888D4448Q52633197-8C6A9AB4-9199-4AFF-8443-54AD31D40AFFQ55466335-332EE356-E738-427F-8092-CF8E420FCED8Q57082684-2725DED1-34D8-4AEF-B6C6-ABED1ABBFCFAQ57298068-68C1F1FB-21CB-4905-9776-443B1D10D1FCQ58003032-43E5DEA6-BEC3-470C-8F85-61CF1D7141A4
P2860
TP53 status for prediction of sensitivity to taxane versus non-taxane neoadjuvant chemotherapy in breast cancer (EORTC 10994/BIG 1-00): a randomised phase 3 trial.
description
2011 nî lūn-bûn
@nan
2011 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
TP53 status for prediction of ...... ): a randomised phase 3 trial.
@ast
TP53 status for prediction of ...... ): a randomised phase 3 trial.
@en
TP53 status for prediction of ...... chemotherapy in breast cancer
@nl
type
label
TP53 status for prediction of ...... ): a randomised phase 3 trial.
@ast
TP53 status for prediction of ...... ): a randomised phase 3 trial.
@en
TP53 status for prediction of ...... chemotherapy in breast cancer
@nl
prefLabel
TP53 status for prediction of ...... ): a randomised phase 3 trial.
@ast
TP53 status for prediction of ...... ): a randomised phase 3 trial.
@en
TP53 status for prediction of ...... chemotherapy in breast cancer
@nl
P2093
P2860
P1433
P1476
TP53 status for prediction of ...... ): a randomised phase 3 trial.
@en
P2093
Alain Lortholary
David A Cameron
EORTC 10994/BIG 1-00 Study Investigators
Elisabet Lidbrink
Emmanuel Blot
Etienne Brain
Hervé Bonnefoi
Jan Bogaerts
Jonas Bergh
Khalil Zaman
P2860
P304
P356
10.1016/S1470-2045(11)70094-8
P577
2011-05-11T00:00:00Z